Market Overview

CEL-SCI Announces That the NYSE American Approves Plan


CEL-SCI Corporation (NYSE:CVM) announces that the NYSE
American (the "Exchange") has accepted the Company's plan to bring
itself into compliance with the Exchange's continued listing standards.

The Company previously received notice from the Exchange on July 12,
2018, indicating the Company is below compliance with Section
1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii) since it
reported a stockholders' equity deficit as of June 30, 2018 and had net
losses in its 5 most recent fiscal years ended September 30, 2017.
Additional information and provisions regarding the NYSE American
requirements are found in Part 10 of its Company Guide. The Company was
afforded the opportunity to submit a plan to regain compliance, and on
July 30, 2018 the Company submitted its plan to the Exchange.

On August 16, 2018 the Exchange notified the Company that it accepted
the Company's plan of compliance and granted the Company until January
14, 2019 to regain compliance with the continued listing standards. The
Company will be subject to periodic review during this period. Failure
to make progress consistent with the plan or to regain compliance with
the continued listing standards by the end of the period could result in
the Company being delisted from the NYSE American. The Company may then
appeal a staff determination to initiate such proceedings in accordance
with the exchange's Company Guide.

"We are very pleased that the NYSE American has accepted our compliance
plan. Continued listing on the NYSE American is highly beneficial to
CEL-SCI and its shareholders and we look forward to regaining full
compliance," stated CEL-SCI CEO Geert Kersten.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient's immune system while it is
still intact should provide the greatest possible impact on survival.
Therefore, in the Phase 3 study CEL-SCI treats patients who are newly
diagnosed with advanced primary squamous cell carcinoma of the head and
neck with Multikine first, BEFORE they receive surgery, radiation and/or
chemotherapy. This approach is unique. Most other cancer immunotherapies
are administered only after conventional therapies have been tried
and/or failed. Multikine (Leukocyte Interleukin, Injection), has
received Orphan Drug designation from the FDA for the neoadjuvant
therapy in patients with squamous cell carcinoma (cancer) of the head
and neck.

CEL-SCI's Phase 3 study is the largest Phase 3 study in the world for
the treatment of head and neck cancer. Per the study's protocol, newly
diagnosed patients with advanced primary squamous cell carcinoma are
treated with the Multikine treatment regimen for 3 weeks prior to the
Standard of Care (SOC) which involves surgery, chemotherapy and/or
radiation. Multikine is designed to help the immune system "see" the
tumor at a time when the immune system is still relatively intact and
thereby better able to mount an attack on the tumor. The aim of
treatment with Multikine is to boost the body's immune system prior to

The Company's LEAPS technology is currently being developed as a
therapeutic vaccine for rheumatoid arthritis and is supported by grants
from the National Institutes of Health. The Company has operations in
Vienna, Virginia, and in/near Baltimore, Maryland.

Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. When
used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements are
subject to risks and uncertainties that could cause actual results to
differ materially from those projected. Such statements include, but are
not limited to, statements about the terms, expected proceeds, use of
proceeds and closing of the offering. Factors that could cause or
contribute to such differences include, an inability to duplicate the
clinical results demonstrated in clinical studies, timely development of
any potential products that can be shown to be safe and effective,
receiving necessary regulatory approvals, difficulties in manufacturing
any of the Company's potential products, inability to raise the
necessary capital and the risk factors set forth from time to time in
CEL-SCI's filings with the Securities and Exchange Commission, including
but not limited to its report on Form 10-K for the year ended September
30, 2017. The Company undertakes no obligation to publicly release the
result of any revision to these forward-looking statements which may be
made to reflect the events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.

View Comments and Join the Discussion!